| Predicate |
Object |
| contentType |
Editorial|Research Support, N.I.H., Extramural|Comment |
| endingPage |
170 |
| issn |
1058-4838
1537-6591 |
| issueIdentifier |
2 |
| pageRange |
169-170 |
| publicationName |
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America |
| startingPage |
169 |
| hasFundingAgency |
http://rdf.ncbi.nlm.nih.gov/pubchem/organization/MD5_199db1bef4b0308c0639203aa0befa4f |
| isSupportedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_0bd792355931076e10ad61ee9e1bfbad
http://rdf.ncbi.nlm.nih.gov/pubchem/grant/MD5_f61551595900eedceabe31321146ad4b |
| bibliographicCitation |
Saag MS. Editorial commentary: getting smart in how we pay for HCV drugs: KAOS vs CONTROL. Clin Infect Dis. 2015 Jul 15;61(2):169–70. doi: 10.1093/cid/civ221. PMID: 25778748. |
| creator |
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_8dd74bc7621df8552025aeef4ad0c82f |
| date |
2015-03-16^^<http://www.w3.org/2001/XMLSchema#date> |
| identifier |
https://doi.org/10.1093/cid/civ221
https://pubmed.ncbi.nlm.nih.gov/25778748 |
| isPartOf |
https://portal.issn.org/resource/ISSN/1537-6591
https://portal.issn.org/resource/ISSN/1058-4838
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/1135 |
| language |
English |
| source |
https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/ |
| title |
Editorial Commentary:Getting Smart in How We Pay for HCV Drugs: KAOS vs CONTROL |
| discusses |
http://id.nlm.nih.gov/mesh/M0001518 |
| hasPrimarySubjectTerm |
http://id.nlm.nih.gov/mesh/D019698Q000191
http://id.nlm.nih.gov/mesh/D000998Q000627
http://id.nlm.nih.gov/mesh/D000998Q000191
http://id.nlm.nih.gov/mesh/D019698Q000188 |
| hasSubjectTerm |
http://id.nlm.nih.gov/mesh/D005260
http://id.nlm.nih.gov/mesh/D006801
http://id.nlm.nih.gov/mesh/D008297 |